Extracellular vesicles can modulate numerous processes starting from proliferation and tissue restore, to chemo-resistance and mobile differentiation. With the introduction of tissue and immunological focusing on, extracellular vesicles are additionally more and more seen as promising vectors to ship peptide-based most cancers antigens to the human immune system.
Despite the medical relevance and therapeutic potential of such ‘cell-free’ approaches, the pure antigen presentation landscape exported in extracellular vesicles remains to be largely uncharted, as a result of the difficult nature of such preparations and analyses. In the context of therapeutic vesicle manufacturing, a essential analysis of the similarity in vesicular antigen presentation can also be urgently wanted. In this work, we in contrast the HLA-I peptide ligandomes of extracellular vesicles towards that of whole-cells of the similar cell line.
We discovered that extracellular vesicles not solely over-represent HLA-B complexes and peptide ligands, but additionally cysteinylated peptides that will modulate immune responses. Collectively, these findings describe the pre-existing provision of vesicular HLA complexes which may be utilized to hold peptide vaccines, in addition to the propensity for various peptide and post-translationally modified ligands to be introduced, and will define essential concerns in devising novel EV vaccination methods.
Bioorthogonal protein labelling allows the examine of antigen processing of citrullinated and carbamylated auto-antigens
Proteolysis is key to many organic processes. In the immune system, it underpins the activation of the adaptive immune response: degradation of antigenic materials into quick peptides and presentation thereof on main histocompatibility complexes, results in activation of T-cells. This initiates the adaptive immune response towards many pathogens.
Studying proteolysis is tough, as the oft-used polypeptide reporters are vulnerable to proteolytic sequestration themselves. Here we current a brand new method that permits the imaging of antigen proteolysis all through the processing pathway in an unbiased method. By incorporating bioorthogonal functionalities into the protein in place of methionines, antigens will be adopted throughout degradation, while leaving reactive sidechains open to templated and non-templated post-translational modifications, corresponding to citrullination and carbamylation.
Using this method, we adopted and imaged the post-uptake destiny of the generally used antigen ovalbumin, in addition to the post-translationally citrullinated and/or carbamylated auto-antigen vinculin in rheumatoid arthritis, revealing variations in antigen processing and presentation. Zika virus (ZIKV) has emerged as an vital world well being risk, with the not too long ago acquired capability to trigger extreme neurological signs and to persist inside host tissues.
We beforehand demonstrated that an early Asian lineage ZIKV isolate induces a extremely activated CD8 T cell response particular for an immunodominant epitope in the ZIKV envelope protein in wild-type mice. Here we present {that a} modern ZIKV isolate from the Brazilian outbreak severely limits CD8 T cell immunity in mice and blocks era of the immunodominant CD8 T cell response. This is related to a extra sustained an infection that’s cleared between 7- and 14-days post-infection.
Mechanistically, we show that an infection with the Brazilian ZIKV isolate reduces the cross-presentation capability of dendritic cells and fails to completely activate the immunoproteasome. Thus, our examine supplies an isolate-specific mechanism of host immune evasion by one Brazilian ZIKV isolate, which differs from the early Asian lineage isolate and supplies potential perception into viral persistence related to current ZIKV outbreaks.
Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy considerably will increase the efficiency of anti-PD1 checkpoint remedy
Clinical immunotherapy approaches are missing efficacy in the therapy of glioblastoma (GBM). In this examine, we sought to reverse native and systemic GBM-induced immunosuppression utilizing the Helicobacter pylori neutrophil-activating protein (NAP), a potent TLR2 agonist, as an immunostimulatory transgene expressed in an oncolytic measles virus (MV) platform, retargeted to permit viral entry by means of the urokinase-type plasminogen activator receptor (uPAR).
While single-agent murine anti-PD1 therapy or repeat in situ immunization with MV-s-NAP-uPA offered modest survival profit in MV-resistant syngeneic GBM fashions, the mixture therapy led to synergy with a remedy charge of 80% in mice bearing intracranial GL261 tumors and 72% in mice with CT-2A tumors.
Combination NAP-immunovirotherapy induced huge inflow of lymphoid cells in mouse mind, with CD8+ T cell predominance; therapeutic efficacy was CD8+ T cell dependent. Inhibition of the IFN response pathway utilizing the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the mind and additional potentiated the therapeutic impact of MV-s-NAP-uPA and anti-PD1.
Our findings help the notion that MV strains armed with bacterial immunostimulatory antigens signify an efficient technique to beat the restricted efficacy of immune checkpoint inhibitor-based therapies in GBM, making a promising translational technique for this deadly mind tumor. One case was optimistic for HLA class I and HLA class II antibodies, whereas 9 circumstances have been optimistic for HLA class II antibodies, and the gene loci have been HLA-DR and/or DQ.
Antibody-mediated rejection (AMR) occurred in 4 of 10 sufferers in the DSA-positive group. Liver perform was irregular in 3 of 38 circumstances in the DSA-negative group. Multivariate evaluation revealed that DSA positivity was an impartial danger issue for liver insufficiency and long-term survival of recipients. In addition, Kaplan-Meier survival evaluation demonstrated that there have been vital variations in the survival of graft recipients between the DSA-positive group and the DSA-negative group (P<0.05).
Goat A' E. coli (all antigens) |
|||
| MBS315044-1mL | MyBiosource | 1mL | 770 EUR |
Goat A' E. coli (all antigens) |
|||
| MBS315044-5x1mL | MyBiosource | 5x1mL | 3290 EUR |
Goat A' E. coli (all antigens) |
|||
| MBS315045-1mL | MyBiosource | 1mL | 885 EUR |
Goat A' E. coli (all antigens) |
|||
| MBS315045-5x1mL | MyBiosource | 5x1mL | 3815 EUR |
E. coli (O+K antigens) goat polyclonal antibody, HRP |
|||
| BP2022HRP | Origene Technologies GmbH | 1 ml | Ask for price |
E. coli (O+K antigens) goat polyclonal antibody, FITC |
|||
| BP2022F | Origene Technologies GmbH | 1 ml | Ask for price |
E. coli (O+K antigens) rabbit polyclonal antibody, HRP |
|||
| BP1021HRP | Origene Technologies GmbH | 1 ml | Ask for price |
E. coli (O+K antigens) goat polyclonal antibody, Biotin |
|||
| BP2022B | Origene Technologies GmbH | 1 ml | Ask for price |
E. coli (O+K antigens) rabbit polyclonal antibody, Biotin |
|||
| BP1021B | Origene Technologies GmbH | 1 ml | Ask for price |
E. coli (O+K antigens) rabbit polyclonal antibody, Purified |
|||
| BP1021 | Origene Technologies GmbH | 1 ml | Ask for price |
Escherichia coli (E. coli) (O & K antigens) (AP) |
|||
| MBS6404757-01mL | MyBiosource | 0.1mL | 875 EUR |
Escherichia coli (E. coli) (O & K antigens) (AP) |
|||
| MBS6404757-5x01mL | MyBiosource | 5x0.1mL | 3785 EUR |
Escherichia coli (E. coli) (O & K antigens) (PE) |
|||
| MBS6404762-01mL | MyBiosource | 0.1mL | 875 EUR |
Escherichia coli (E. coli) (O & K antigens) (PE) |
|||
| MBS6404762-5x01mL | MyBiosource | 5x0.1mL | 3785 EUR |
Escherichia coli (E. coli) (O & K antigens) (APC) |
|||
| MBS6404758-01mL | MyBiosource | 0.1mL | 875 EUR |
Escherichia coli (E. coli) (O & K antigens) (APC) |
|||
| MBS6404758-5x01mL | MyBiosource | 5x0.1mL | 3785 EUR |
Escherichia coli (E. coli) (O & K antigens) (HRP) |
|||
| MBS6404761-01mL | MyBiosource | 0.1mL | 875 EUR |
Escherichia coli (E. coli) (O & K antigens) (HRP) |
|||
| MBS6404761-5x01mL | MyBiosource | 5x0.1mL | 3785 EUR |
Escherichia coli (E. coli) (O & K antigens) (HRP) |
|||
| MBS6404767-01mL | MyBiosource | 0.1mL | 820 EUR |
Escherichia coli (E. coli) (O & K antigens) (HRP) |
|||
| MBS6404767-5x01mL | MyBiosource | 5x0.1mL | 3530 EUR |
Escherichia coli (E. coli) (O & K antigens) (FITC) |
|||
| MBS6404760-01mL | MyBiosource | 0.1mL | 875 EUR |
Escherichia coli (E. coli) (O & K antigens) (FITC) |
|||
| MBS6404760-5x01mL | MyBiosource | 5x0.1mL | 3785 EUR |
Escherichia coli (E. coli) (O & K antigens) (FITC) |
|||
| MBS6404766-01mL | MyBiosource | 0.1mL | 820 EUR |
Escherichia coli (E. coli) (O & K antigens) (FITC) |
|||
| MBS6404766-5x01mL | MyBiosource | 5x0.1mL | 3530 EUR |
E. coli (O+K antigens) goat polyclonal antibody, Ig Fraction |
|||
| BP2022 | Origene Technologies GmbH | 1 ml | Ask for price |
Escherichia coli (E. coli) (O & K antigens) (Biotin) |
|||
| MBS6404759-01mL | MyBiosource | 0.1mL | 875 EUR |
Escherichia coli (E. coli) (O & K antigens) (Biotin) |
|||
| MBS6404759-5x01mL | MyBiosource | 5x0.1mL | 3785 EUR |
Escherichia coli (E. coli) (O & K antigens) (Biotin) |
|||
| MBS6404765-01mL | MyBiosource | 0.1mL | 820 EUR |
Escherichia coli (E. coli) (O & K antigens) (Biotin) |
|||
| MBS6404765-5x01mL | MyBiosource | 5x0.1mL | 3530 EUR |
RSV Antibody (all antigens) |
|||
| GWB-F26ED3 | GenWay Biotech | 1 ml | Ask for price |
Chlamydia trachomatis (EB's all antigens) Antibody |
|||
| abx022942-1ml | Abbexa | 1 ml | 710.4 EUR |
Chlamydia trachomatis (EB's all antigens) Antibody |
|||
| abx022942-400l | Abbexa | 400 µl | Ask for price |
Chlamydia trachomatis (EB's all antigens) Antibody |
|||
| abx022942-80l | Abbexa | 80 µl | 1012.5 EUR |
H.pylori all antigens |
|||
| hpy-250 | Clemente Associates LLC | 2 ML | 414.75 EUR |
Listeria all antigens |
|||
| lis-250 | Clemente Associates LLC | 2 ML | 414.75 EUR |
Chlamydia trachomatis (EB's all antigens) Antibody (HRP) |
|||
| abx022943-1ml | Abbexa | 1 ml | 777.6 EUR |
Chlamydia trachomatis (EB's all antigens) Antibody (HRP) |
|||
| abx022943-400l | Abbexa | 400 µl | Ask for price |
Chlamydia trachomatis (EB's all antigens) Antibody (HRP) |
|||
| abx022943-80l | Abbexa | 80 µl | 1150 EUR |
Chlamydia trachomatis (EB's all antigens) Antibody (FITC) |
|||
| abx022939-1ml | Abbexa | 1 ml | 710.4 EUR |
Chlamydia trachomatis (EB's all antigens) Antibody (FITC) |
|||
| abx022939-400l | Abbexa | 400 µl | Ask for price |
Chlamydia trachomatis (EB's all antigens) Antibody (FITC) |
|||
| abx022939-80l | Abbexa | 80 µl | 1112.5 EUR |
Chlamydia trachomatis (EB's all antigens) Antibody (FITC) |
|||
| abx022940-1ml | Abbexa | 1 ml | 710.4 EUR |
Chlamydia trachomatis (EB's all antigens) Antibody (FITC) |
|||
| abx022940-400l | Abbexa | 400 µl | Ask for price |
Chlamydia trachomatis (EB's all antigens) Antibody (FITC) |
|||
| abx022940-80l | Abbexa | 80 µl | 1162.5 EUR |
Goat anti RSV (all antigens) |
|||
| MBS315209-1mL | MyBiosource | 1mL | 770 EUR |
Goat anti RSV (all antigens) |
|||
| MBS315209-5x1mL | MyBiosource | 5x1mL | 3290 EUR |
Neisseria gonorrhoeae (all antigens) rabbit polyclonal antibody, HRP |
|||
| BP1050HRP | Origene Technologies GmbH | 1 ml | Ask for price |
Neisseria gonorrhoeae (all antigens) rabbit polyclonal antibody, Biotin |
|||
| BP1050B | Origene Technologies GmbH | 1 ml | Ask for price |
Neisseria meningitidis (all antigens) rabbit polyclonal antibody, FITC |
|||
| BP1051F | Origene Technologies GmbH | 1 ml | Ask for price |
Neisseria gonorrhoeae (all antigens) rabbit polyclonal antibody, Purified |
|||
| BP1050 | Origene Technologies GmbH | 1 ml | Ask for price |
Mycobacterium tuberculosis (all antigens) rabbit polyclonal antibody, HRP |
|||
| BP2027HRP | Origene Technologies GmbH | 1 ml | Ask for price |
Mycobacterium tuberculosis (all antigens) rabbit polyclonal antibody, FITC |
|||
| BP2027F | Origene Technologies GmbH | 1 ml | Ask for price |
Mycobacterium tuberculosis (all antigens) rabbit polyclonal antibody, Biotin |
|||
| BP2027B | Origene Technologies GmbH | 1 ml | Ask for price |
Mycobacterium tuberculosis (all antigens) rabbit polyclonal antibody, Purified |
|||
| BP2027 | Origene Technologies GmbH | 1 ml | Ask for price |
Mycoplasma pneumoniae (all antigens) rabbit polyclonal antibody, Ig Fraction |
|||
| BP1049 | Origene Technologies GmbH | 1 ml | Ask for price |
Neisseria meningitidis (all antigens) rabbit polyclonal antibody, Ig Fraction |
|||
| BP1051 | Origene Technologies GmbH | 1 ml | Ask for price |
Rabbit Anti-Mycoplasma pneumoniae IgG (all antigens) |
|||
| MPPN12-A | Alpha Diagnostics | 100 ug | 578.4 EUR |
Rh Blood Group CcEe Antigens (RHCE) Antibody |
|||
| abx339688-100g | Abbexa | 100 µg | Ask for price |
Rh Blood Group CcEe Antigens (RHCE) Antibody |
|||
| 20-abx339688 | Abbexa |
|
|
Rh Blood Group CcEe Antigens (RHCE) Antibody |
|||
| abx339688-20g | Abbexa | 20 µg | 250 EUR |
Rh Blood Group CcEe Antigens (RHCE) Antibody |
|||
| abx339688-50g | Abbexa | 50 µg | 350 EUR |
Rh Blood Group CcEe Antigens (RHCE) Antibody |
|||
| abx211379-100l | Abbexa | 100 µl | 350 EUR |
Rh Blood Group CcEe Antigens (RHCE) Antibody |
|||
| 20-abx211379 | Abbexa |
|
|
Rh Blood Group CcEe Antigens (RHCE) Antibody |
|||
| abx211379-50l | Abbexa | 50 µl | 250 EUR |
Rh Blood Group CcEe Antigens (RHCE) Antibody |
|||
| abx376106-96tests | Abbexa | 96 tests | 337.5 EUR |
Rh Blood Group CcEe Antigens (RHCE) Antibody |
|||
| abx413595-02mg | Abbexa | 0.2 mg | 678 EUR |
Rh Blood Group CcEe Antigens (RHCE) Antibody |
|||
| abx413595-200l | Abbexa | 200 µl | 462.5 EUR |
Rh Blood Group CcEe Antigens (RHCE) Antibody |
|||
| abx413596-200l | Abbexa | 200 µl | 175 EUR |
Rh Blood Group CcEe Antigens (RHCE) Antibody |
|||
| abx413596-25ug | Abbexa | 25 ug | 326.4 EUR |
Toxoplasma Antigens |
|||
| GWB-BE735D | GenWay Biotech | 1 mg | Ask for price |
E. coli Antibody (all ag\ s) |
|||
| GWB-2B4FD0 | GenWay Biotech | 1 ml | Ask for price |
E. coli Antibody (all ag\ s) |
|||
| GWB-B791A4 | GenWay Biotech | 1 ml | Ask for price |
E. coli Antibody (all ag\ s) |
|||
| GWB-FFCFD6 | GenWay Biotech | 1 ml | Ask for price |
E. coli Antibody (all ag\ s) |
|||
| GWB-D6A8DE | GenWay Biotech | 1 ml | Ask for price |
EBV Early Antigens |
|||
| MBS438342-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
EBV Early Antigens |
|||
| MBS438342-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
EBV Early Antigens |
|||
| MBS438342-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
EBV Early Antigens |
|||
| MBS438342-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
EBV Early Antigens |
|||
| MBS438342-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
Rubella Virus Antigens |
|||
| GWB-8DCDE6 | GenWay Biotech | 1 mg | Ask for price |
Anti-Rat Tumor Antigens of Epithelial Origin antibody |
|||
| STJ16100726 | St John's Laboratory | 100 µg | 1164 EUR |
Anti-Rat Tumour Antigens of Epithelial Origin antibody |
|||
| STJ16100727 | St John's Laboratory | 100 µg | 1164 EUR |
Salmonella (O+H antigens) rabbit polyclonal antibody, HRP |
|||
| BP1063HRP | Origene Technologies GmbH | 1 ml | Ask for price |
Salmonella (O+H antigens) rabbit polyclonal antibody, FITC |
|||
| BP1063F | Origene Technologies GmbH | 1 ml | Ask for price |
Recombiant (E. coli) Hepatitis C Virus (Hepatitis C Virus (HCV) Antigens-GST fusion protein (mosaic of several antigenic epitopes) (soluble) |
|||
| HCV36-R | Alpha Diagnostics | each | 343.2 EUR |
Salmonella (O+H antigens) rabbit polyclonal antibody, Biotin |
|||
| BP1063B | Origene Technologies GmbH | 1 ml | Ask for price |
Salmonella (O+H antigens) rabbit polyclonal antibody, Purified |
|||
| BP1063P | Origene Technologies GmbH | 1 ml | Ask for price |
Hepatitis A Virus Antigens |
|||
| GWB-F8E2AE | GenWay Biotech | 1 ml | Ask for price |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx140231-01mg | Abbexa | 0.1 mg | 444 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx140231-100g | Abbexa | 100 µg | 287.5 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx140253-01mg | Abbexa | 0.1 mg | 444 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx140253-100g | Abbexa | 100 µg | 287.5 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx140254-01mg | Abbexa | 0.1 mg | 444 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx140254-100g | Abbexa | 100 µg | 287.5 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx140257-01mg | Abbexa | 0.1 mg | 444 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx140257-100g | Abbexa | 100 µg | 287.5 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx200524-100ug | Abbexa | 100 ug | 393.6 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx413474-02mg | Abbexa | 0.2 mg | 678 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx413474-200l | Abbexa | 200 µl | 462.5 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx415437-025mg | Abbexa | 0.25 mg | 678 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx415437-200l | Abbexa | 200 µl | 462.5 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx415449-02mg | Abbexa | 0.2 mg | 678 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody |
|||
| abx415449-200l | Abbexa | 200 µl | 462.5 EUR |
Epstein-Barr Virus Antigens |
|||
| GWB-439063 | GenWay Biotech | 1 ml | Ask for price |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE) |
|||
| abx140294-100g | Abbexa | 100 µg | 400 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE) |
|||
| abx140294-100tests | Abbexa | 100 tests | 577.2 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE) |
|||
| abx140305-100g | Abbexa | 100 µg | 400 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE) |
|||
| abx140305-100tests | Abbexa | 100 tests | 577.2 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE) |
|||
| abx200526-100tests | Abbexa | 100 tests | 543.6 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE) |
|||
| abx413475-200l | Abbexa | 200 µl | 487.5 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE) |
|||
| abx415436-200l | Abbexa | 200 µl | 487.5 EUR |
Escherichia coli (E Coli) O157 Antigen |
|||
| MBS569542-01mL | MyBiosource | 0.1mL | 515 EUR |
Escherichia coli (E Coli) O157 Antigen |
|||
| MBS569542-5x01mL | MyBiosource | 5x0.1mL | 2110 EUR |
EBV Early Antigens 12-well |
|||
| EA-12 | Fuller Laboratories | each | 30 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC) |
|||
| abx140295-100g | Abbexa | 100 µg | 400 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC) |
|||
| abx140295-100tests | Abbexa | 100 tests | 577.2 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC) |
|||
| abx140306-100g | Abbexa | 100 µg | 400 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC) |
|||
| abx140306-100tests | Abbexa | 100 tests | 577.2 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC) |
|||
| abx200527-100tests | Abbexa | 100 tests | 760.8 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (RPE) |
|||
| abx413475-100tests | Abbexa | 100 tests | 710.4 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (RPE) |
|||
| abx415436-100tests | Abbexa | 100 tests | 710.4 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PerCP) |
|||
| abx140293-100g | Abbexa | 100 µg | 400 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PerCP) |
|||
| abx140293-100tests | Abbexa | 100 tests | 577.2 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PerCP) |
|||
| abx200528-100tests | Abbexa | 100 tests | 543.6 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (FITC) |
|||
| abx415435-01mg | Abbexa | 0.1 mg | 610.8 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (FITC) |
|||
| abx415435-200l | Abbexa | 200 µl | 400 EUR |
Hepatitis A Virus (HAV) Antigens |
|||
| HAV17-N-10 | Alpha Diagnostics | 10 ug | Ask for price |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE / DL594) |
|||
| abx140339-100g | Abbexa | 100 µg | 437.5 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (OC-515) |
|||
| abx200531-100tests | Abbexa | 100 tests | 560.4 EUR |
EBV Early Antigens IgG IFA Kit |
|||
| EAG-120 | Fuller Laboratories | each | 435 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (CF-Blue) |
|||
| abx200530-100tests | Abbexa | 100 tests | 577.2 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC-C750) |
|||
| abx200532-100tests | Abbexa | 100 tests | 1195.2 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (CF-Blue) |
|||
| abx200534-100tests | Abbexa | 100 tests | 577.2 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PerCP-Cy5.5) |
|||
| abx200533-100tests | Abbexa | 100 tests | 577.2 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PerCP-Cy5.5) |
|||
| abx200535-100tests | Abbexa | 100 tests | 927.6 EUR |
Escherichia coli, O157 Somatic Antigen (E. coli) |
|||
| MBS602479-1mg | MyBiosource | 1mg | 1230 EUR |
Escherichia coli, O157 Somatic Antigen (E. coli) |
|||
| MBS602479-5x1mg | MyBiosource | 5x1mg | 5375 EUR |
Rabbit Anti-Borrelia burgdorferi (whole antigens) IgG |
|||
| BBA12-A | Alpha Diagnostics | 100 ul | 562.8 EUR |
Rabbit Anti-E. coli all ag's Polyclonal Antibody |
|||
| DPAB0123 | Creative Diagnostics | 1 ml | 619.92 EUR |
|
Description: Rabbit |
|||
Rabbit Anti-E. coli all ag's Polyclonal Antibody |
|||
| DPAB0126 | Creative Diagnostics | 1 ml | 719.04 EUR |
|
Description: Rabbit |
|||
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE / Cyanine 5) |
|||
| abx347061-100l | Abbexa | 100 µl | Ask for price |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE / Cyanine 5) |
|||
| abx347061-50l | Abbexa | 50 µl | 400 EUR |
Sheep Anti-Borrelia burgdorferi (whole antigens) antiserum |
|||
| BBA11-S | Alpha Diagnostics | 100 ul | 562.8 EUR |
Native E. coli O157 Antigen |
|||
| DAG-WT1173 | Creative Diagnostics | 100 µL | 750 EUR |
|
Description: Native |
|||
Rabbit Anti-Treponema Pallidum (Syphilis) protein antiserum (recognizes all major syphilis antigens) |
|||
| SPL11-S | Alpha Diagnostics | 100 ul | 548.4 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE-DyLight 594) |
|||
| abx140339-100tests | Abbexa | 100 tests | 627.6 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC / Cyanine 7) |
|||
| abx140948-100g | Abbexa | 100 µg | 437.5 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC / Cyanine 7) |
|||
| abx347010-100g | Abbexa | 100 µg | Ask for price |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC / Cyanine 7) |
|||
| abx347010-20g | Abbexa | 20 µg | 437.5 EUR |
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC / Cyanine 7) |
|||
| abx347010-50g | Abbexa | 50 µg | Ask for price |
The positivity of DSAs after pediatric liver transplantation was intently associated to the incidence of AMR. These outcomes prompt that DSAs needs to be routinely monitored post-operatively, and that DSA-positive recipients needs to be screened as quickly as attainable and given acceptable therapy.